Best of ASH 2014
Best of ASH 2014
ASH 2014: Highlights in CLL from ASH 2014
Oprozomib shows potential in the treatment of multiple myeloma
Ibrutinib as a single agent and in combination with dexamethasone showed anti-tumour activity in multiple myeloma
Combination therapy for high-risk MDS? Not quite yet
Results of HD2000 trial comparing combination therapies in advanced-stage Hodgkin's lymphoma
ASH 2014: Highlights in mantle cell lymphoma
ASH 2014: Highlights in multiple myeloma
Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia
New cytarabine combinations could overcome toxicities in AML treatment
Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults
Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia